Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

Rhea-AI Summary

Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.

The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.

CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.

Positive

• Obtained radioactive materials license for in-house preclinical studies
• Integration of radionuclide testing with existing PDX platform creates unique market position
• Expanded capabilities in radiotherapeutics development and assessment

Negative

• None.

HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.

Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.

"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."

This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.

For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us.

About Champions Oncology

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Inquiries:

Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com

Website: https://www.championsoncology.com/

Facebook: https://www.facebook.com/championsoncology/

LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/

Twitter: @ChampionsOncol1

Instagram: https://www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the significance of Champions Oncology's new radioactive materials license?

The license enables Champions Oncology to conduct in-house radionuclide-based therapeutic testing combined with their PDX models, enhancing their capabilities in radiotherapeutic development and assessment.

How will CSBR's new license impact their radiopharmaceutical development capabilities?

The license allows Champions to integrate radionuclide-based therapeutic testing with their PDX platform, improving their ability to support partners in developing next-generation radiotherapeutics with better translational precision.

What types of therapeutic modalities will Champions Oncology (CSBR) support with their new license?

Champions will support drug developers working with antibody-radionuclide conjugates and peptide receptor radionuclides through their comprehensive testing program.

How does Champions Oncology's PDX platform complement their new radioactive materials license?

The PDX platform provides clinically relevant models that can now be combined with radionuclide-based therapeutic testing in-house, offering a unique integrated approach to radiopharmaceutical development.